TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $421,923 | -48.4% | 47,195 | -11.4% | 0.00% | -60.0% |
| Q2 2023 | $817,797 | +54347.2% | 53,242 | -20.3% | 0.01% | -56.5% |
| Q1 2023 | $1,502 | +164.4% | 66,770 | +147.3% | 0.02% | +109.1% |
| Q4 2022 | $568 | -99.9% | 27,004 | -15.4% | 0.01% | -35.3% |
| Q3 2022 | $786,000 | -63.4% | 31,912 | -61.8% | 0.02% | -66.0% |
| Q1 2022 | $2,150,000 | +10.8% | 83,437 | +33.5% | 0.05% | +56.2% |
| Q4 2021 | $1,940,000 | +41.0% | 62,509 | +10.1% | 0.03% | +45.5% |
| Q3 2021 | $1,376,000 | +17.8% | 56,752 | -29.1% | 0.02% | 0.0% |
| Q2 2021 | $1,168,000 | – | 80,067 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |